Delivery Order SPE2DB22D3016-SPE2DB26FABC4
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for GAMUNEX-C 20 gram/200 milliliter vials valued at $11,801.40 with firm fixed pricing. This is a non-set-aside delivery order with an ultimate completion date of September 3, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, is executing this...
- The Defense Logistics Agency awarded a delivery order valued at $11,801.40 to AmerisourceBergen Drug Corp for GAMUNEX-C 20 gram/200 mL vials on September 29, 2025, with completion scheduled for October 21, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitive award under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to the contractor's facility in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 20, 2025, for the supply of GAMUNEX-C 10 gram/100 mL vials valued at $6,092.18 with a completion date of November 10, 2025. This firm fixed-price, competitively awarded contract involves no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,743.66 to AmerisourceBergen Drug Corp for the supply of GAMUNEX-C 20 gram/200 milliliter vials on September 15, 2025, with an ultimate completion date of October 6, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract involves the delivery of an immunoglobulin...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of GAMUNEX-C 10 gram/100 mL vials valued at $1,220.94. This is a firm fixed-price delivery order with an ultimate completion date of August 20, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,360.28 to AmerisourceBergen Drug Corp for GAMUNEX-C 20 gram/200 mL vials. This firm fixed price delivery order, awarded on August 22, 2025, with a completion date of September 15, 2025, represents a single pharmaceutical supply transaction under a larger indefinite delivery contract. GAMUNEX-C is an immunoglobulin product used for treating immunodeficiency conditions and represents the type of specialized pharmaceutical...
- The Defense Logistics Agency awarded a $23,272.00 firm fixed-price delivery order to AmerisourceBergen Drug Corp for GAMUNEX-C (40 gram/400 ml vial), with an ultimate completion date of August 13, 2025. This is an unset-aside, competitively awarded contract that will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. As a child order under a larger contract vehicle, this delivery order represents a single transaction within AmerisourceBergen's extensive pharmaceutical...
- The Defense Logistics Agency awarded a $6,981.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of GAMUNEX-C 40 Gram/400 ML Vial (400ML). The contract is classified as a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This delivery order carries an ultimate completion date of October 6, 2025, and was awarded...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 5, 2025, for the supply of GAMUNEX-C 40 gram/400 milliliter vials, with a contract ceiling value of $11,636.00 and an ultimate completion date of June 27, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $46,954.09 to AmerisourceBergen Drug Corp for the supply of GAMUNEX-C 40 gram/400 mL vials. This firm fixed-price delivery order, awarded on June 2, 2025, is scheduled for completion by June 24, 2025, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. The award was made through competitive procurement with no set-aside designation, reflecting the contractor's capability to meet...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB26FABC4Delivery Order
The Defense Logistics Agency has awarded a delivery order valued at $10,743.66 to AmerisourceBergen Drug Corp for the supply of GAMUNEX-C 20 gram/200 mL vials. This firm fixed price delivery order, issued on November 3, 2025, with completion scheduled for November 25, 2025, is being fulfilled from the contractor's facility in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement and supplies an extensive range of pharmaceutical products and medical commodities to support military healthcare programs. GAMUNEX-C, an immunoglobulin product, aligns with the company's portfolio of specialty medications delivered through the DLA Medical Supply Chain to support Defense Health Agency requirements and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.7k | 11/3/25 |